Chimeric Therapeutics ASX: CHM

The ASX Leader in #CellTherapy

#CLTXCART #Chlorotoxin #NKCells $CHM

[Chimeric Therapeutics ASX: CHM @Chimeric]

Chimeric CAR T therapy delivers durable disease control in early GI cancer trial | $CHM Media coverage by @AusBiotech
https://t.co/g0fWXpdekb l

[Chimeric Therapeutics ASX: CHM @Chimeric]

We've achieved 82% stable disease per RECIST, with 9 of 11 evaluable patients achieving stable disease. $CHM CDH17 expanded & persisted in all treated patients, with evidence of disease control in heavily pre-treated metastatic cancer patients.
https://t.co/V5AZN49T1d

[Chimeric Therapeutics ASX: CHM @Chimeric]

We’re in Philadelphia visiting Minaris for a closer look at a manufacturing run for $CHM CDH17. CEO Dr Rebecca McQualter and Head of Manufacturing Dr Agathe Bourgogne visited the site as CHM CDH17 progresses through Phase 1/2 clinical development in gastrointestinal cancers.

[Chimeric Therapeutics ASX: CHM @Chimeric]

“We’re just about to hit a very big inflection point.”
From our CEO Dr Rebecca McQualter, speaking with @wholesaleinvest.
🎥 Watch the $CHM interview below.
https://t.co/IDgchSAWac
#CellTherapy #Oncology #Biotech #ASX #Chimeric

[Chimeric Therapeutics ASX: CHM @Chimeric]

Our Quarterly Activities Report for the period ending 31 March 2026 has been released.
View the full $CHM report: https://t.co/bOJ0jcxEpN

[Chimeric Therapeutics ASX: CHM @Chimeric]

Top 10 at 11: Chimeric has complete response in 60pc of leukemia cohort | $CHM Medica coverage by @StockheadAU.
https://t.co/hpBIfdnyT8

[Chimeric Therapeutics ASX: CHM @Chimeric]

We’ve achieved 60% CR/CRi in the ADVENT-AML NCT05834244 Phase 1B clinical trial, with 25 patients enrolled, 60% have demonstrated complete responses. High risk, frontline patients are being treated with CHM CORE-NK + standard of care.
https://t.co/CgO3smprx9
$CHM #Biotech

[Chimeric Therapeutics ASX: CHM @Chimeric]

Our CEO Dr Rebecca McQualter, will join industry leaders in #Rome this month to moderate “From Phase 1 to BLA: Early Decisions that Impact Global Expansion” on 29 April, 11:30am CET.
The panel includes leaders from Autolus Therapeutics, Cabaletta Bio and Cellares. $CHM

[Chimeric Therapeutics ASX: CHM @Chimeric]

From CEO Dr Rebecca McQualter at the NWR Healthcare Conference: A $CHM CDH17 patient has reached 15 months with no new tumours, maintaining chemotherapy-free progression-free survival. CHM CDH17 has now advanced to Dose Level 3.
🎥 Watch the full replay:
https://t.co/tL3eoAhbgG

[Chimeric Therapeutics ASX: CHM @Chimeric]

The replay of our CEO, Dr Rebecca McQualter’s presentation from today’s NWR Virtual Healthcare Conference is now available.

Watch the full replay here: https://t.co/LBjWUirREA

#ChimericTherapeutics #CHM #HealthcareConference #Biotech #InvestorUpdate #Fibrosis #ASX @NWRcomms

[Chimeric Therapeutics ASX: CHM @Chimeric]

Our CEO Dr Rebecca McQualter presented at the @NWRcomms Virtual Healthcare Conference today.

View the full presentation: https://t.co/sE23HtUYSQ

#ChimericTherapeutics $CHM #HealthcareConference #Biotech #InvestorUpdate #Webinar #Fibrosis #MedicalResearch #ASX

[Chimeric Therapeutics ASX: CHM @Chimeric]

REMINDER | CEO Dr. Rebecca McQualter will present tomorrow at 10:00 am AEDT (25 March) at the
@NWRcomms Healthcare Conference.

📌 Register here: https://t.co/sb3ipOX4iw

Questions can be submitted to: [email protected].

More info: https://t.co/WR08kKVxSn

$CHM

[Chimeric Therapeutics ASX: CHM @Chimeric]

CEO Dr. Rebecca McQualter will present at 10:00am AEDT on 25 March 2026 at the @NWRcomms Healthcare Conference.

📌 Register here: https://t.co/sb3ipOX4iw

Questions can be submitted live or in advance via [email protected].

More info: https://t.co/WR08kKVxSn
$CHM

[Chimeric Therapeutics ASX: CHM @Chimeric]

Letter to Shareholders: March 2026
View the full $CHM Announcement here: https://t.co/ffJzDnGrLs

[Chimeric Therapeutics ASX: CHM @Chimeric]

In case you missed it: @Chimeric was featured in @StockheadAU's #Health & #Biotech Investor Guide 2026.
The segment highlights our lead CAR-T therapy $CHM CDH17, early patient outcomes from our US Phase 1/2 trial, and our focus on tackling solid tumours.
Watch the feature below.

[Chimeric Therapeutics ASX: CHM @Chimeric]

March is Colorectal Cancer Awareness Month. $CHM CDH17 is being studied in advanced colorectal cancer and other gastrointestinal cancers in our Phase 1/2 trial. Our focus is progressing CHM CDH17 through clinical development advancing new potential treatment options for patients.

[Chimeric Therapeutics ASX: CHM @Chimeric]

We’ve received $1,785,000 from Radium Capital under a funding facility secured against our anticipated FY26 Research and Development Tax Incentive. Funds will support our clinical trial pipeline and general working capital.
https://t.co/S2t5MaXBFF
$CHM #CellTherapy

[Chimeric Therapeutics ASX: CHM @Chimeric]

We've released our Half-year Report ended 31 December 2025.
View the full $CHM report here: https://t.co/vFyKjFW1jA

[Chimeric Therapeutics ASX: CHM @Chimeric]

We’ve entered into an arrangement to return CHM CLTX to City of Hope. Following a strategic review, the Board determined this represents a disciplined capital management decision aligned with our focus on advancing $CHM CDH17.
https://t.co/aqyjqzULdb

[Chimeric Therapeutics ASX: CHM @Chimeric]

We’re featured in the latest @StockheadAU Investor Guide, highlighting the progress of our US clinical programs and the patient impact driving our work.

Read more in the latest Stockhead Investor Guide: https://t.co/UMtXWJd6QB

$CHM